Physician profile
Michael J Sineway
NPI 1962488080
$5,929.61
in general payments reported to CMS, 2019-2025
36 companies · $990 in 2025
The $990 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $569 · 2021: $295 · 2022: $994 · 2023: $782 · 2024: $959 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,612 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.99 |
| Education | $119.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $969.99 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $862.10 | 2019-2025 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $815.82 | 2019-2025 | Airsupra, Farxiga, Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $441.82 | 2024-2025 | |
| Insmed, INC. | $372.00 | 2019-2023 | Arikayce |
| Genzyme Corporation | $370.36 | 2019-2025 | |
| Amgen INC. | $315.46 | 2021-2025 | Repatha, Tezspire, Repatha |
| Regeneron Healthcare Solutions, INC. | $213.70 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $134.75 | 2019 | |
| Mylan Specialty L.P. | $122.73 | 2019-2022 | |
| Novo Nordisk INC | $111.44 | 2024-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $105.16 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| United Therapeutics Corporation | $94.77 | 2021-2023 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $89.65 | 2019-2023 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 3b Medical, INC. | $87.12 | 2025 | Luna |
| Exact Sciences Corporation | $83.31 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $75.29 | 2025 | Veozah |
| Abbvie INC. | $63.55 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $62.58 | 2023-2024 | Rexulti, Nuedexta |
| Actelion Pharmaceuticals US, INC. | $55.25 | 2019-2024 | Opsumit |
| Philips North America LLC | $54.29 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $54.17 | 2019-2020 | |
| Lilly USA, LLC | $51.37 | 2025 | Zepbound |
| Sunovion Pharmaceuticals INC. | $34.50 | 2019 | |
| Resmed Corp | $29.16 | 2022 | |
| Ani Pharmaceuticals, INC. | $24.05 | 2023 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $19.99 | 2020 | |
| Mallinckrodt Enterprises LLC | $19.87 | 2019 | |
| Gilead Sciences, INC. | $16.38 | 2022 | |
| Ethicon US, LLC | $15.43 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.98 | 2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $13.25 | 2023 | Glassia |
| Teva Pharmaceuticals USA, INC. | $13.02 | 2022 | |
| Grifols USA, LLC | $11.88 | 2021 | |
| Daiichi Sankyo INC. | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sineway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.